Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kumarapillai Mohanan Nair Jagathnath Krishna"'
Autor:
Ramachandran Krishna Chandran, Narayanan Geetha, Kunnathur Murugesan Sakthivel, Raveendran Suresh Kumar, Kumarapillai Mohanan Nair Jagathnath Krishna, Hariharan Sreedharan
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The emergence of additional chromosomal abnormalities (ACAs) in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia (CML), is considered to be a feature of disease evolution. However, their frequency of incidence, impact on prognosis a
Externí odkaz:
https://doaj.org/article/6d051bd32026448ca60a16ea3d437225
Autor:
Narayanan Geetha, Kumarapillai Mohanan Nair Jagathnath Krishna, Kunnathur Murugesan Sakthivel, Hariharan Sreedharan, Thampirajan Vimaladevi Akhila Raj, Ramachandran Krishna Chandran
Publikováno v:
Journal of Environmental Pathology, Toxicology and Oncology. 40:51-64
The clinical implications of cohesin gene complex mutation in acute myeloid leukemia (AML) are not well characterized. In the present study, a cohort of 152 de novo unselected adult AML patients underwent conventional and molecular cytogenetic analys
Autor:
Narayanan Geetha, Ramachandran Krishna Chandran, Raveendran Suresh Kumar, Kumarapillai Mohanan Nair Jagathnath Krishna, Kunnathur Murugesan Sakthivel, Hariharan Sreedharan
Publikováno v:
Blood Cells, Molecules, and Diseases. 77:51-60
The molecular mechanisms responsible for disease progression of CML are not conclusive. The main functional changes associated with disease evolution in CML was high proliferation rate, decreased apoptosis, blockade of differentiation, and strong res
Autor:
Ramachandran Krishna Chandran, Narayanan Geetha, Kunnathur Murugesan Sakthivel, Raveendran Suresh Kumar, Kumarapillai Mohanan Nair Jagathnath Krishna, Hariharan Sreedharan
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology, Vol 9 (2019)
The emergence of additional chromosomal abnormalities (ACAs) in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia (CML), is considered to be a feature of disease evolution. However, their frequency of incidence, impact on prognosis a